Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity.

导出 OA

翻译打印收藏纠错

作者： Mario,de la Fuente Revenga ^[1] ; Daisuke,Ibi ^[1] ; Travis,Cuddy ^[2] ; Rudy,Toneatti ^[3] ; Mitsumasa,Kurita ^[1] ; Maryum K,Ijaz ^[1] ; Michael F,Miles ^[2] ; Jennifer T,Wolstenholme ^[4] ; Javier,González-Maeso ^[1]

作者单位： Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. ^[1] Department Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. ^[2] Department of Chemical Pharmacology, Meijo University, Nagoya, 468-8503, Japan. ^[3] Dainippon Sumitomo Pharma Co., Ltd., Osaka, 564-0053, Japan. ^[4] Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. ^[5] VCU Alcohol Research Center, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. ^[6] Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. javier.maeso@vcuhealth.org. ^[7] Department Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. javier.maeso@vcuhealth.org. ^[8] Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. javier.maeso@vcuhealth.org. ^[9] Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. javier.maeso@vcuhealth.org. ^[10]